Non-alcoholic fatty liver had been believed to be a non-progressive benign disease. However, Ludwig et al. described some patients who exhibited progressive steatohepatitis without habitual alcohol drinking (Ludwig et al., 1980) and referred to this disease as non-alcoholic steatohepatitis (NASH). Later, NASH and non-progressive simple steatosis patients were included in the single disease enti...

Background: Non-alcoholic steatohepatitis (NASH) is an emerging disease belonging to the non-alcoholic fatty liver disease (NAFLD) spectrum, which may progress to fibrosis and thereby to cirrhosis of the liver. Currently, no definitive and effective treatment strategies have been identified to treat NASH. Objective: To study the effect of pioglitazone, quercetin, and hydroxy citric acid on lipi...

Nonalcoholic steatohepatitis (NASH) is a condition histologically similar to alcoholic steatohepatitis, yet while the latter has long been recognized as a cause of end-stage liver disease, the former was, until recently, discounted as having a benign course [1–3]. Indeed, it was felt that undisclosed alcohol use must account for those individuals with advanced fibrosis and steatohepatitis [4]. ...

Drug-induced liver diseases (DILD) are clinico-pathologic patterns of liver injury caused by drugs or other foreign compounds. Steatohepatitis is a rare form of DILD, and drugs account for fewer than 2% of non-alcoholic steatohepatitis (NASH). Drugs known to be capable of inducing steatosis and steatohepatitis can be divided into three broad groups: those that cause steatosis and steatohepatiti...

Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). NAFLD is characterized by excessive fat accumulation in the liver (steatosis), without any other evident causes of...

It has come to our attention that the excel files of following supplementary tables were not included during online publication article: Table S3, S4, S8, S9, S13, and S14. These have now been made available online. We apologize for any inconvenience caused. Molecular characterisation hepatocellular carcinoma in patients with non-alcoholic steatohepatitisJournal HepatologyVol. 75Issue 4PreviewN...

Prevalence of non-alcoholic steatohepatitis (NASH) rises steadily in Western countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposes to cirrhosis and associated morbi-mortality. The cannabinoid system is increasingly emerging as a crucial mediator of acute and chronic liver injury. Recent experimental and clinical data indicate that peripher...

Non-alcoholic steatohepatitis (NASH) is a component of a wide spectrum of diseases that go from non-alcoholic fatty liver disease (NAFLD) to cirrhosis, and hepatocellular carcinoma in 40-60% of patients with NASH-related cirrhosis in a 5-7 year follow-up [1]. NASH has become one of the leading causes of liver disease in the developed world. With NAFLD believed to have doubled in the past 20 yea...

objective(s):non-alcoholic steatohepatitis (nash), is an important component of non-alcoholic fatty liver disease (nafld) spectrum, which progresses to the end stage liver disease, if not diagnosed and treated properly. the disproportionate production of pro- and anti-inflammatory adipokines secreted from fat contributes to the pathogenesis of nash. in this study, the comparative effect of piog...

Non-alcoholic fatty liver disease (NAFLD) is emerging as a major health problem worldwide. NAFLD is a continuum of disease ranging from mild liver steatosis to severe steatohepatitis, which will ultimately lead to end-stage liver disease with high morbidity and mortality rates. This disorder is considered as a silent liver disease. The metabolic syndrome and its components are accounted as the ...